Introduction

Kallikrein 6 (KLK6) is a secreted serine protease and member of the largest contiguous cluster of serine proteases in the human genome. In prior studies we have demonstrated elevated levels of KLK6 occur in active MS lesions and in the serum of patients experiencing a secondary progressive disease course. KLK6 levels have also been shown to be present in infiltrating immune cells at sites of CNS inflammation in animal models of MS and to be up regulated in T cells with activation [1,2,3,4]. Additionally, blocking KLK6 activity diminishes clinical and histological disease as well as Th1 inflammatory responses in experimental autoimmune encephalomyelitis (EAE) [5], yet the role and mechanism of action of KLK6 in immune function has not been previously examined.

While best characterized for its ability to degrade extracellular matrix factors including laminin, fibronectin and heat denatured collagen [6,7], in addition to myelin proteins [1], KLK6 has also been recently demonstrated to activate a subset of protease activated receptors (PAR) [8,9,10,11]. PARs are G-protein coupled transmembrane receptors that are uniquely activated by proteolytic cleavage and well known to play key roles in driving inflammatory responses. Of the four known PARs, KLK6 has been recently demonstrated to activate a subset of protease activated receptors (PAR) [8,9,10,11]. PARs are G-protein coupled transmembrane receptors that are uniquely activated by proteolytic cleavage and well known to play key roles in driving inflammatory responses. Of the four known PARs, KLK6 has been shown to activate PAR1 in neurons and both PAR1 and PAR2 in astrocytes triggering intracellular Ca<sup>2+</sup> flux and differentially affecting both MAPK and AKT signaling pathways [11]. KLK6 was also shown to activate PAR2 in HEK cells to trigger Ca<sup>2+</sup> signaling and on aortic endothelial cells to mediate relaxation [9]. Whether KLK6 induces signaling in lymphocytes and the dependence of this on PAR has not been previously addressed.

The physiological actions of PARs have perhaps been most extensively studied in terms of their regulation of immune responses. PAR-specific activities have been described in both

Abstract

Background: Kallikrein 6 (KLK6) is a newly identified member of the kallikrein family of secreted serine proteases that prior studies indicate is elevated at sites of central nervous system (CNS) inflammation and which shows regulated expression with T cell activation. Notably, KLK6 is also elevated in the serum of multiple sclerosis (MS) patients however its potential roles in immune function are unknown. Herein we specifically examine whether KLK6 alters immune cell survival and the possible mechanism by which this may occur.

Methodology/Principal Findings: Using murine whole splenocyte preparations and the human Jurkat T cell line we demonstrate that KLK6 robustly supports cell survival across a range of cell death paradigms. Recombinant KLK6 was shown to significantly reduce cell death under resting conditions and in response to camptothecin, dexamethasone, staurosporine and Fas-ligand. Moreover, KLK6-over expression in Jurkat T cells was shown to generate parallel pro-survival effects. In mixed splenocyte populations the vigorous immune cell survival promoting effects of KLK6 were shown to include both T and B lymphocytes, to occur with as little as 5 minutes of treatment, and to involve up regulation of the pro-survival protein Bcl-XL, and inhibition of the pro-apoptotic protein Bcl-2-interacting mediator of cell death (Bim). The ability of KLK6 to promote survival of splenic T cells was also shown to be absent in cell preparations derived from PAR1 deficient mice.

Conclusion/Significance: KLK6 promotes lymphocyte survival by a mechanism that depends in part on activation of PAR1. These findings point to a novel molecular mechanism regulating lymphocyte survival that is likely to have relevance to a range of immunological responses that depend on apoptosis for immune clearance and maintenance of homeostasis.

Citation: Scarisbrick IA, Epstein B, Cloud BA, Yoon H, Wu J, et al. (2011) Functional Role of Kallikrein 6 in Regulating Immune Cell Survival. PLoS ONE 6(3): e18376. doi:10.1371/journal.pone.0018376

Funding: Mayo Collaborative MS Research Award CA1060A11-02, the Christopher and Dana Reeve Foundation and NCI PS0CA108961, National Institutes of Health Grants NS052741 and R15NS057771 (http://www.nih.gov/) and the National Multiple Sclerosis Society Grants RG3367 (http://www.nationalmssociety.org/index.aspx). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: Scarisbrick.Isobel@Mayo.edu

Copyright: © 2011 Scarisbrick et al. This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
innate and adaptive immunity, including roles in mast cells, eosinophils, basophils, monocytes, dendritic cells and T cells (see [12] for review). For example, mast cell tryptase, known to activate PAR2, promotes synthesis and release of pro-inflammatory cytokines from peripheral blood mononuclear cells [13]. PAR1 and -2 activation in monocytes and dendritic cells results in increased GM-CSF and IL-6, but reduced IL-4 [14,15,16]. In T and B cells, PAR1 activation promotes proliferation and augments T cell CD3 and IL-2 responses [17]. Studies using PAR deficient mice indicate a duality of PAR function depending on the context with both pro- and anti-inflammatory roles being reported. For example, in rodents PAR1 has been shown to play an anti-inflammatory role in cases of *H. pylori* induced gastritis [18], but exacerbates inflammation in a murine model of colitis [19], crescentic glomerulonephritis [20], and BSA induced arthritis [21]. PAR2 has been demonstrated to play an anti-inflammatory role in airways [22] and intestine [19], but a role in disease exacerbation in adjuvant induced arthritis [23], allergic dermatitis [24] and in EAE [25].

Given the abundant expression of KLK6 by T cells and monocytes at sites of CNS inflammation, in the serum of patients with secondary progressive MS, and its regulation by immune cell activation, determination the likely role[s] of this unique serine protease in immune function is long overdue. Herein we examine the effect of KLK6 on lymphocyte survival and the possible role of PAR1. Results indicate KLK6 promotes survival of murine splenocytes by a mechanism that depends in part on activation of PAR1 and which involves at least in part the up regulation of pro-survival and down regulation pro-apoptotic Bcl-2 family member signaling proteins.

**Materials and Methods**

**Ethics Statement**

All animal experiments were carried out with strict adherence to NIH Guidelines for animal care and safety and were approved by the Mayo Clinic Institutional Animal Care and Use Committee, Animal Welfare Assurance number A3291-01, and Protocol number A26508.

**Model Systems**

The effect of KLK6 on immune cell survival was examined using whole splenocyte populations derived from C57BL/6/J or PAR1 deficient mice or the Jurkat T-leukemic cell line (clone E6-1, TIB-152 American Type Culture Collection). Eight to 12 week old C57 mice were obtained from Jackson Laboratories. Mice deficient in PAR1 were harvested from Jackson Laboratories. Mice deficient in PAR1 (B6.129S4-P2y11-1/J) were also obtained from Jackson and backcrossed to C57BL6/J for 10 generations, such that C57 mice served as wild type controls in each experiment. KLK6-Over Expression

**Cell Culture**

Spleens were homogenized in RPMI-1640, red blood cells lysed with ammonium chloride buffer, and splenocytes cultured in tissue culture treated 96 well plates at a density of 7.5×10⁶ cells/ml. All experiments were performed in serum free X-Vivo media (Lonza, Mapleton, IL) containing 2 mM Glutamax, 1 mM sodium pyruvate, 50 U/mL penicillin-streptomycin, 10 mM HEPES, 50 μM 2-β-mercaptoethanol and 10 μM non-essential amino acids (Invitrogen). Jurkat T cells were maintained in log-phase growth in the same defined media. All cells were maintained at 37°C in 95% air and 5% CO₂. All culture conditions were examined in triplicate within a given experiment and all experiments repeated at least twice.

**Reagents**

Recombinant KLK1 and KLK6 were expressed using a baculovirus/insect system, purified and activated as previously described in detail [6,7,26]. We have developed expression systems for both *Homo sapiens* and *Rattus norvegicus* KLK6 [6,7]. Phylogenetic analysis identifies *Homo sapiens* KLK6 and *Rattus norvegicus* KLK6 as unambiguous orthologs [6]. In a pair-wise comparison of the KLK6 proteins of these species there are no insertions or deletions of amino acids. The mature proteins are 223 amino acids in length in each case. The functional activity of *Rattus norvegicus* and *Homo sapiens* KLK6 mature proteins can be directly compared for digestions of myelin basic protein, laminin and fibronectin and these show essentially identical specificities; and the conservation of the regulatory autolytic inactivation property for each protein has also been demonstrated [6,7]. The characteristic preference for arginine versus lysine in the substrate P1 position has also been directly compared between *Rattus norvegicus* and *Homo sapiens* KLK6 mature proteins using identical tripeptide substrates and has been demonstrated to be highly-conserved in these species orthologs. *Mus musculus* KLK6 contains two additional amino acids at the C-terminus but since this is anti-podal to the active site it would have no known effect upon enzyme activity or specificity and therefore is predicted to be identical in function to the human and rat forms. Thus, the available evidence supports a highly-conserved sequence, functional activity, and substrate specificity between mouse, rat and human KLK6 orthologs. The primary observation in this report, that KLK6 improves survival of murine splenocytes and the human Jurkat T cell line, has been observed in experiments which utilized either the *Rattus norvegicus* or *Homo sapiens* forms of KLK6, and all experiments shown were carried out using *Rattus norvegicus* KLK6. All experiments involving KLK1 utilized highly purified recombinant *Homo sapiens* KLK1 [26]. Use of *Homo sapiens* KLK1 to study physiological effects in a murine system has been previously validated [27]. The functional activity of recombinant KLKs were examined at concentrations ranging from 1 to 10 μg/ml (40 to 400 nM) which correspond to concentrations that our prior studies have shown induce intracellular signaling [11]. The concentrations of KLK6 examined also encompass the physiologic level seen in normal cerebrospinal fluid (0.5–2 μg/ml [28,29,30] and up to 5-fold excess which we anticipate partially models the elevated levels seen at sites of CNS inflammation in MS and its animal models [1,2,3,4].

**KLK6-Over Expression**

Results demonstrated using recombinant KLK6 were confirmed in Jurkat T cells using a KLK6 over expression system. Jurkat T cells were transduced with a vector in which the *Homo sapiens* KLK6 gene (NM_002774) is under the control of a cytomegalovirus (CMV) promoter (GeneCopoeia, Inc., Rockville, MD), or the corresponding empty vector, by electroporation using a Genetronics BTX T820 square-wave electroporator (San Diego, CA). Stably transduced Jurkat cells were selected using 0.4 mg/ml G418 (Invitrogen, Carlsbad, CA). All experiments described were carried out in serum free X-Vivo media without the addition of G418. Levels of KLK6 over expression in stable cell lines were quantified by real time PCR as previously described in detail [3]. Briefly, total RNA was extracted from G418-selected Jurkat cells transduced with KLK6-CMV, or vector alone, using RNA STAT-60 (Tel-Test, Inc. Friendswood, TX) and 0.5 μg of total RNA.
subject to RT-PCR using the Light Cycler-RNA Amplification Kit (SYBR Green I (Roche Diagnostics, Mannheim, Germany) and an i-Cycler iQ Real-Time PCR instrument (BioRad, Hercules, CA). KLK6 expression levels were normalized to those for glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Forward and reverse primers for *Homo sapiens* KLK6 were Forward, 5′-TGGCGAGGTAGTTGGG-3′ and Reverse 5′-TGGCGAGCTTGTGTGAAGTGC-3′; and for GAPDH were Forward 5′-ACCACTCATGGGAGGC-3′ and Reverse 5′-GGCATTGGACTGTG-3′. Expression levels in each case were quantified relative to standard curves resulting from amplification of KLK6 or GAPDH nucleic acid templates.

**Cell Death Paradigms**

To determine the scope of action of KLK6 in altering immune cell survival we examined its effects in a range of cell death paradigms, including those mediated by transmembrane death receptors, such as the Fas receptor (extrinsic pathway), and those which result from cellular stress and activation of intracellular mitochondrial signaling cascades (intrinsic pathways)[31]. Signaling through the Fas receptor is known to directly activate apoptosis by recruitment and activation of caspase enzymes [32] and was induced in the present study using Fas ligand/TNFSF6 (2 μg/ml) cross linked with anti-polyHistidine (10 μg/ml). Several activators of intrinsic apoptotic mechanisms were also examined, including spontaneous (resting) cell death, known to occur after harvest and plating of splenocytes in vitro [33] and staurosporine-induced cell death (0.1 to 1 μM), which occurs by broad spectrum protein kinase inhibition [34,35]. Other activators of intrinsic apoptotic mechanisms were also examined such as the glucocorticoid dexamethasone (0.1 μM), which is widely used as an anti-inflammatory and T cell apoptotic agent [36,37] and the topoisomerase inhibitor camptothecin (1.0 μM), which was originally developed as an anti-cancer therapeutic. Concanavalin A (ConA, 5 μg/ml) is a lectin and well known lymphocyte mitogen that promotes activation induced cell death [38]. Since camptothecin-induced lymphocyte apoptosis is enhanced in the presence of mitogens [39], we examined the effects of KLK6 on cell death induced by either camptothecin or ConA alone, or in combination. All agents utilized to induce cell death were obtained from Sigma and were either applied to cultures at the time of plating simultaneously with KLK6, or after cultures had first been pre-incubated with KLK6 for 2 hr.

**Flow Cytometry**

Following experimental incubation periods which ranged from 4 to 72 hr, cells were harvested and stained with combinations of antibodies recognizing to CD45, CD3, B220 or the early apoptotic marker Annexin-V, conjugated to FITC, PE, or APC (eBioscience, San Diego, CA). In each case, either propidium iodide (PI) or 7-Aminoactinomycin D (7AAD) were used to label dead cells (Sigma). Examination of the composition of the splenocyte cultures examined revealed that the CD45+ T lymphocytes with 24% being CD3+ T lymphocytes and 60% being B220+ B lymphocytes, while less than 2.5% were CD11b+ monocytes. Cells were analyzed by flow cytometry using a FACSCalibur flow cytometer (BD Biosciences, Mountain View, CA). Live immune cells were defined as those which were positive for the common leukocyte antigen CD45, but negative for PI. Early and late apoptotic/dead cells were distinguished using a combination of AnnexinV-Phycocerythrin (PE) and 7AAD or AnnexinV-Fluorescein isothiocyanate (FITC) and PI (BD Biosciences). FlowJo software (Ashland, OR) was used to quantify different cell populations in flow cytometry experiments. Potential effects on cell proliferation were examined by labeling cells with carboxyfluorescein succinimidyl ester [40,41] (CFSE, Invitrogen, Carlsbad, CA) prior to plating followed by analysis using the FlowJo proliferation platform at the completion of each experiment.

To compare multiple cell culture conditions within a given experiment, the mean and standard error (SEM) across experimental groups were analyzed by One-Way Analysis of Variance (ANOVA) followed by Student-Newman-Keuls (SNK) post hoc test except when data were not normally distributed when ANOVA on Ranks and Mann-Whitney-U analyses were performed. Statistical differences between two groups were compared using the Student’s t-test or the Rank Sum test when data were non-linear. P<0.05 was considered statistically significant. All samples were analyzed in triplicate and experiments repeated at least 3 separate times, using independent cell culture preparations, with parallel results.

**Western Blot Analysis**

Protein lysates from whole splenocyte cell cultures were separated on SDS-polyacrylamide gels prior to transfer to nitrocellulose membranes. Antibodies to detect Bcl-2XL and Bim were obtained from Cell Signaling Technology (Danvers, MA). The Poly AD-ribose polymerase (PARP) antibody was a kind gift from Dr. S. Kaufmann [42]. Equal loading was verified by probing blots for β-Actin (Novus, Littleton, CO). In all cases proteins of interest were detected on film using chemiluminescence (Pierce, Rockford, IL). For quantification, films were scanned and images quantified using Image Lab 2.0 software (BioRad). Relative changes in BIM and BCL-XL protein levels in resting or treated cells were determined by normalizing optical density measurements for either protein with those for Actin detected on the same membrane. In the case of PARP, in which level of cleavage was the end point of interest, both the upper band corresponding to 116 kDa intact form, and the signature 89-kDa caspase-generated fragment [43] were each normalized to Actin. The percent PARP cleavage was then determined by calculating the percent that the 89-kDa fragment was of the total PARP (116+89 kDa fragments) detected. All Western blots were repeated at least twice using separate cell culture preparations with similar results.

**Results**

**KLK6 differentially affects immune cell survival and proliferation**

As a first approach to define the possible immunological actions of KLK6, its effects on survival and proliferation of murine splenocytes were examined and compared to another kallikrein family member, KLK1. While KLK6 did not significantly alter splenocyte proliferation after 24 or 72 hr, it did promote a substantial and dose dependent reduction in the number of cells positive for markers of cell death across the same time points (Fig 1, see also Figs. 2, 3, 4, 5, 6, 7, 8). Significant reductions in the number of PI positive dead cells were observed under resting conditions when splenocytes were cultured in the presence of either 1 or 10 μg/ml of KLK6 at the time of plating. Since 10 μg/ml of KLK6 generated the most robust rescue this concentration was carried forward in all subsequent experiments. Also, KLK6 promoted cell survival at both 24 and 72 hr time points such that most subsequent experiments were carried out to 24 hr. Parallel examination of a second kallikrein, KLK1, generated by baculovirus expression in parallel with KLK6 [26], did not significantly impact cell survival. KLK1 (10 μg/ml) did however promote a significant increase in the percent of divided cells when
examined 24 hr post-stimulation. Significant differences in proliferation were not seen at lower concentrations of KLK1, or when cells were examined at 72 hr. The significance of KLK1’s mitogenic effects toward splenocytes will need to be followed up in future studies. The general lack of KLK6-induced proliferative effects support the hypothesis that overall changes in splenocyte survival and death observed across experiments were not due to KLK6-mediated changes in cell proliferation.

**KLK6 promotes survival of T cells and B cells across multiple cell death paradigms**

To determine whether promotion of lymphocyte survival represents a fundamental feature of KLK6 biology, we examined its ability to reduce cell death across a range of paradigms. KLK6 not only reduced the death of splenocytes which occurs after explant and culture (Resting, Figs. 1, 2, 3, 4, 5, 6, 7), but also that seen in response to 0.1 μM dexamethasone (Figs. 2, 3, 7). KLK6 also reduced the death of splenocytes induced by 1 μM staurosporine (Fig. 5) and in response to 2 μg/ml Fas ligand (Fig. 2). Co-labeling of splenocytes with CD3 to label T lymphocytes, and B220 to label B lymphocytes, in conjunction with 7AAD to identify cell death, indicated that KLK6 reduced the number of dead cells in both populations in resting cultures and in response to dexamethasone (Fig. 7). Parallel to observations using mixed splenocyte preparations, and supporting strong KLK6-mediated effects toward T lymphocytes, recombinant KLK6 also significantly diminished Jurkat T cell death under resting conditions and when exposed to 1 μM camptothecin or 1 μM camptothecin plus 5 μg/ml ConA, and in response to Fas ligand receptor cross linking (Figs. 2, 4). The ability of KLK6 to rescue splenocytes or Jurkat T cells across cell death paradigms was consistently observed when KLK6 was applied simultaneously with death inducing agents. A two hour pre-incubation with KLK6 prior to dexamethasone application was shown to result in a small but statistically significant enhancement of survival (Fig. 2, P<0.05).

To determine whether prolonged or continual exposure to KLK6 was necessary to promote significant rescue effects, we compared the pro-survival effects of abbreviated periods of KLK6 stimulation (Fig. 3). Interestingly, the pro-survival effects of KLK6 over a 24 hr period under resting conditions or in the presence of dexamethasone were similar when whole splenocyte cultures were treated with KLK6 for 5, 30 or 60 min, or for the full 24 hr period of culture. However when experimental endpoints were extended to 48 hr, only continual treatment with KLK6, but not transient exposure up to 60 min, was sufficient to promote more prolonged pro-survival effects.

In addition to examination of the effects of recombinant KLK6, we additionally determined whether over expression of the KLK6 gene in the Jurkat T cell line would similarly alter the extent of cell death observed (Fig. 6). Jurkat cells were stably transduced with a vector in which the KLK6 gene is constitutively expressed under control of the CMV promoter, or empty vector, and KLK6 expression levels quantified by real time PCR [3]. Similar to KLK6 transcript levels we have previously reported in Jurkat T cells, mean KLK6 transcript levels (± SEM) were 5.5E+05 ± 2.5E+04 in cells transduced with vector alone and 2.65E+07 ± 1.0E+04 in KLK6-CMV transduced cells. GAPDH transcript levels in the same samples were 4.0E+06 ± 1.7E+05 and 3.9E+06 ± 1.8E+05, respectively, demonstrating equal RNA loading. This
represents a 50-fold increase in KLK6 expression levels, a result replicated by PCR more than 3 times using separate cell culture preparations. Importantly, relative to cells transduced with vector alone, those transduced with the KLK6-CMV vector showed a significant increase in the number of live cells (7AAD<sup>-</sup>, Annexin V<sup>-</sup>) and a decrease in the number of dead cells (7AAD<sup>+</sup>, PI<sup>-</sup>) under resting conditions, and when challenged with 0.1 or 0.25 mM staurosporine (Fig. 6).

**Figure 2.** KLK6 decreases death of murine splenocytes and Jurkat T cells across multiple paradigms. KLK6 (10 μg/ml) significantly reduced the number of PI<sup>+</sup> dead splenocytes observed by flow cytometry after a 24 hr period in culture under resting conditions, in response to (0.1 μM) dexamethasone (A), or after 24 hr exposure to Fas ligand (FasL, 2 μg/ml, B). In parallel experiments (C), Jurkat T cells showed significantly reduced levels of cell death under resting conditions and in response to camptothecin (1.0 μM), or Fas ligand (C, 2 μg/ml) when co-treated with KLK6 (10 μg/ml). Fas ligand at 2 μg/ml caused greater cell death in Jurkat cells (C) relative to splenocytes (B) under the conditions of this study. KLK6 was applied at the time of plating in conjunction with cell death inducing agents in each case. A small but significant improvement in the ability of KLK6 to rescue splenocytes from death was seen with a 2 hr pre-incubation prior to the addition of dexamethasone (A); Data are expressed as mean ± SEM of triplicate cultures examined in parallel, One Way ANOVA with SNK post hoc test for multiple comparisons in (A), two-way comparisons A to C, were made using Students t-test; P<0.001***, P=0.005**, P=0.02*.

**Figure 3.** As little as a 5 minute pulse of KLK6 is sufficient to promote splenocyte survival. To gauge the minimal time of exposure to KLK6 necessary to observe its pro-survival effects, splenocytes were pulsed with KLK6 (10 μg/ml) for periods of 5, 30 or 60 min, or in the presence of KLK6 for the full 24 or 48 hr period of culture examined, prior to labeling with PI for analysis of dead cells by flow cytometry (A and B). A 5 min pulse with KLK6 was also sufficient to promote survival when cells were exposed to dexamethasone (0.1 μM) for 24 hr (C). After longer periods of culture however (B, 48 hr), only the more prolonged period of KLK6 stimulation (48 hr) exerted significant pro-survival effects (B). Data shown are the mean ± SEM of triplicate cell culture samples run in parallel and examined by One Way ANOVA with the SNK post hoc test for multiple comparisons; P<0.001**, P=0.005*. Results shown are representative of at least 3 separate experiments using independent cell culture preparations.

In the case of Jurkat T cells under resting conditions, recombinant KLK6 promoted a reduction in the number of dead cells and a corresponding increase in the number of live cells, but did not significantly alter the number of early apoptotic cells when examined at 4, 24 or 48 hr post plating (Fig. 4). When Jurkat cells were challenged with the topoisomerase inhibitor camptothecin, with ConA, or a combination of these agents, KLK6 reduced the number of dead cells at the 4, 24 and 48 hr time points examined, mirroring observations under resting conditions. A significant increase in the number of live cells was also seen in each circumstance except after 48 hr exposure to the Camptothecin or the ConA+Camptothecin combination. Interestingly, Jurkat cells cultured in the presence of KLK6 in addition to ConA, or ConA plus camptothecin, showed an accumulation of cells at early apoptotic stages at the 24 hr time point examined. By 48 hr, KLK6-induced accumulation of early apoptotic cells was seen.
under all three death-inducing conditions, including camptothecin alone. Supporting the concept that KLK6 is able to delay apoptosis under certain conditions, KLK6-CMV over expression in Jurkat cells was also associated with not only an increase in the number of live cells and a decrease in the overall number of dead cells, but in the presence of 0.25 mM staurosprorine, a significant accumulation of AnnexinV+7AAD− early apoptotic cells was also observed (Fig. 6).

Examination of live, early apoptotic, and dead cells in murine splenocyte cultures generated results parallel to those observed in Jurkat T cells, that is KLK6-induced decreases in the percentage of dead cells was accompanied by increases in the number of cells in the live and/or early apoptotic populations depending on the conditions examined (Fig. 5). Under resting conditions over 24 hr, the presence of KLK6 significantly reduced the number of dead cells and a small but significant increase in the live cell population was observed (Fig. 5A). In the presence of dexamethasone (0.1 μM), or staurosporine (1 μM), co-exposure to KLK6 promoted a significant decrease in the number of dead cells and a small but significant increase in the live cell population (Fig. 5B and C).

Figure 4. KLK6 promotes survival of Jurkat T cells in part by slowing the apoptotic cascade. To address the effect of KLK6 on apoptosis, Jurkat T cells were grown under resting conditions (A), or in the presence of apoptosis inducing agents (B to D), then labeled with Annexin V-PE and 7AAD prior to flow cytometry. Under resting conditions (A), and in the presence of camptothecin (B, 1.0 μM), ConA (C, 5 μg/ml), or ConA plus camptothecin (D), KLK6 (10 μg/ml) promoted an increase in the percentage of live cells (unlabeled) and a decrease in the percentage of dead cells (Annexin V+7AAD+) at both acute (4 hr), subacute (24 hr), and in some cases the more chronic time point examined (48 hr). Interestingly, in the presence of apoptosis inducing agents (B to D), KLK6 also promoted a corresponding increase in the percentage of Jurkat T cells positive for Annexin V, but negative for 7AAD, and therefore classified as in the early stages of apoptosis. These results suggest KLK6 may delay but not block the apoptotic cascade. Data shown are for triplicate cultures examined in parallel and are expressed as mean ± SEM, One Way ANOVA with SNK post hoc test for multiple comparisons; P<0.001***, P≤0.005**, P≤0.02*. All results shown are representative of those seen across at least three experiments using independent cell culture preparations.

doi:10.1371/journal.pone.0018376.g004
population. In addition, under these death-inducing conditions, exposure to KLK6 also resulted in a significant accumulation of cells at the early apoptotic stage.

KLK6-mediated lymphocyte survival occurs in T cells and B cells and depends in part on activation of PAR1

To investigate the pro-survival effects mediated by KLK6 toward splenic lymphocytes, and the potential involvement of PAR1, we examined the ability of KLK6 to alter resting or dexamethasone-induced death in whole splenocyte cultures isolated from WT or PAR1 knockout mice and used flow cytometry approaches to specifically examine the response of T and B cell subsets (Fig. 7). The overall extent of cell death (see also Figs. 1, 2, 3, 5), in addition to that occurring specifically in splenic CD3$^+$ T cells, and B220$^+$ B cells, was examined. Basal levels of cell death were not observed to differ significantly between WT and PAR1$^{-/-}$ mice. Under resting conditions, the absence of PAR1 completely blocked the ability of KLK6 to support the survival of splenocytes overall, and in either of the CD3$^+$ T cell or B220$^+$ B cell subsets. In the case of dexamethasone treatment of WT splenocytes, KLK6 was seen to significantly reduce overall cell death and that observed in both CD3$^+$ T cells and B220$^+$ B cells. In splenocytes isolated from PAR1$^{-/-}$ mice, KLK6 was no longer able to significantly decrease dexamethasone induced CD3$^+$ T cell death, although overall cell death and that of B220$^+$ B cells continued to be significantly reduced by KLK6.

The ability of KLK6 to alter apoptosis was further addressed by examining its effects on cleavage of PARP, one of the final caspase substrates cleaved in the apoptotic cascade, in whole splenocyte preparations under resting conditions or when treated with camptothecin or ConA (Fig. 8A). Significant levels of cleaved PARP were detected in WT splenocytes grown under resting conditions and when exposed to camptothecin for 24 hr. In each case, co-treatment with KLK6 significantly reduced the amount of cleaved PARP detected by Western blot.

KLK6 differentially regulates Bcl-2 family member signaling

To begin to address the mechanism by which KLK6 may promote splenocyte survival we examined its effects on Bcl-2 family pro- and anti-apoptotic signaling cascades. Levels of the pro-survival protein Bcl-XL in resting, camptothecin or ConA treated whole splenocyte cultures were below the detection limit of our assay. When splenocytes were exposed to either camptothecin or ConA in the presence of KLK6 however, significant elevations in Bcl-XL were observed (Fig. 8B). KLK6 did not elevate Bcl-XL protein levels in resting splenocyte cultures. Interestingly, KLK6 reduced levels of the pro-apoptotic protein BIM, under resting conditions and in the presence of camptothecin or ConA (Fig. 8B).

**Discussion**

KLK6 levels are elevated at sites of inflammation in active MS lesions, in CNS trauma, and in animal models of these pathologies [1,46]. Elevations are due in part to expression of KLK6 by infiltrating immune cells [1,3,46], yet very little is currently known...
Figure 6. KLK6 over expression in Jurkat T cells reduces cell death. Jurkat T cells were stably transduced with a vector in which the human KLK6 gene is constitutively expressed under the control of a CMV promoter, or with an empty vector (Control), and levels of live (Annexin V-PE- and 7AAD-), early apoptotic (Annexin V-PE+ and 7AAD-), or dead (Annexin V-PE+ and 7AAD+) cells determined by flow cytometry under resting conditions, or after 24 hr periods of exposure to 0.1 or 0.25 μM staurosporine. (A) Histogram and corresponding dot plots (B), demonstrate KLK6 over expression produces effects largely parallel to those afforded by treatment of cultures with recombinant KLK6. There was a decrease in the percentage of dead cells and an increase in the number of live cells in Jurkat T cells over expressing KLK6, relative to those expressing an empty vector. KLK6 over expression also reduced cell death in the presence of 0.1 or 0.25 μM staurosporine relative to that seen in cells stably transduced with empty vector. Reductions in cell death were likely to reflect in part a delay in apoptosis, since after 24 hr exposure to 0.25 μM Staurosporine, KLK6 over expression not only reduced the number of dead cells and increased the number of live cells, but cells in the early stages of apoptosis (AnnV-PE-, 7AAD-) were also significantly elevated. Data are expressed as mean ± SEM of triplicate cultures examined in parallel; One Way ANOVA with SNK post hoc test for multiple comparisons, P <0.001***, P = 0.002**, P = 0.003*. All data shown is representative of that seen in at least 3 independent cell culture experiments.

doi:10.1371/journal.pone.0018376.g006

Figure 7. The ability of KLK6 to reduce murine T and B cell death depends in part on activation of PAR1. To determine the involvement of PAR1 in KLK6-mediated reductions in lymphocyte death, the ability of KLK6 (10 μg/ml) to reduce cell death under resting conditions, or in response to dexamethasone (0.1 μM), was compared between wild type and PAR1-/- splenocytes. Comparisons were made between the total percentage of 7AAD+ dead cells, or between those additionally labeled to recognize CD3+ T cells, or B220+ B cells. (A) KLK6 (10 μg/ml) significantly reduced the overall percentage of 7AAD+ dead cells under resting conditions and in response to dexamethasone (0.1 μM). KLK6-mediated reductions in overall cell death in both paradigms (A) were seen to encompass both CD3+ T lymphocytes (B) and B220+ B lymphocytes (C). The absence of PAR1 (PAR1 KO) impaired the ability of KLK6 to significantly reduce the overall percentage of cell death and that associated with T cells and B cells under resting conditions. The absence of PAR1 also impaired the ability of KLK6 to reduce dexamethasone-induced CD3+ T cell death. Data shown are mean ± SEM of triplicate cultures examined in parallel; One Way ANOVA with SNK post hoc test for multiple comparisons, P <0.001***, P<0.002**, P<0.003**, P<0.05*. Results shown are representative of that seen in at least 3 independent experiments.

doi:10.1371/journal.pone.0018376.g007
regarding the role of this newly identified serine protease in immune function. In this study, we demonstrate that KLK6 exerts pro-survival effects toward murine splenocytes and Jurkat T cells across a range of cell death paradigms. We further demonstrate that the pro-survival effects of KLK6 in splenocytes depend in part on activation of the G-protein coupled receptor, PAR1, and involve at least a subset of Bcl-2 family member signaling cascades. Taken together, these findings delineate KLK6 as a new player within the network of regulatory mechanisms that govern survival of immune cells.

The present studies demonstrate for the first time that KLK6 is able to promote survival of murine splenocytes as well as the human leukemic Jurkat T cell line across divergent cell death paradigms encompassing both the intrinsic/mitochondrial and the extrinsic Fas-Fas ligand-induced apoptotic signaling pathways. The ability of KLK6 to promote survival of T-lymphocytes is supported by observations of its pro-survival effects toward both Jurkat T cells and CD3+ positive cells in whole splenocyte cultures. Notably, we were able to demonstrate robust pro-survival effects of KLK6 toward Jurkat T cells when cells were either treated with recombinant KLK6 or when KLK6 over expression was enforced using a KLK6 expression construct under control of a CMV promoter. The likely fundamental role of KLK6 in lymphocyte survival in general is supported by findings in whole splenocyte cultures that pro-survival effects extend also to B220 positive B-lymphocytes. Contrasting its robust pro-survival effects, KLK6 did not significantly alter splenocyte proliferation under the conditions of this study, indicating that proliferative effects were unlikely to account for its ability to increase the number of viable cells. Interestingly, another member of the KLK family, KLK1, better known as true tissue kallikrein, did exert proliferative effects toward splenocytes in the first 24 hr period of culture. Taken with evidence that both KLK1 and KLK6 are elevated in the serum of MS patients [4], it is tempting to speculate that these proteases may operate in tandem to support inflammation by uniquely enhancing immune cell survival and proliferation.

Experiments examining Annexin V labeling, which is taken as a marker of the early stages of apoptosis, in conjunction with markers of plasma membrane permeabilization, such as PI or 7AAD that are indicative of cell death, suggest KLK6 is capable of delaying the cell death cascade at early stages of apoptosis. While KLK6 increased the number of live cells and decreased the detection of dead cells across a range of cell death paradigms, both in whole splenocyte preparations and in the case of Jurkat T cells, KLK6 also promoted a significant accumulation of cells at the early stages of apoptosis (Annexin V+, PI-). The accumulation of Annexin V positive cells accompanied by a decrease in dead cells was particularly prominent in Camptothecin and ConA treated Jurkat cells carried out to the 48 hr time point. These data favor a model whereby KLK6 delays the apoptotic process. Taken with findings herein that KLK6 also blocks the cleavage of PARP, it is likely that KLK6 delays the apoptotic cascade from entering into the effector phase when caspase 3 activation and PARP cleavage occur.

The mechanism by which KLK6 promotes lymphocyte survival was shown to involve, at least in part, activation of the thrombin receptor PAR1. Using genetically PAR1 deficient mice the present studies demonstrate that the absence of PAR1 completely blocks the ability of KLK6 to reduce the final stages of death of T- and B-lymphocytes under resting conditions. While there is growing evidence regarding the role of PAR activation in inflammation [47,48], particularly with regard to roles in driving cytokine production and proliferation, this is the first report of the likely involvement of PAR1 activation in the control of lymphocyte survival. Of interest in this regard, several recent studies have demonstrated a role for PAR1 in survival of non-immune cells including, prostate cancer cells via NFKB and activation of Bcl-XL [49], breast cancer cells via activation of AKT [50], CC139 fibroblasts by suppression of Bim [51], and rat astrocytes by release of chemokine growth-regulated oncogene/cytokine-induced neutrophil chemoattractant-1 [52]. The present in vitro results suggest that the anti-inflammatory effects of PAR1 deficiency, already described in some murine models, may relate in part to the absence of pro-survival signaling mediated by certain agonists such as KLK6 at this receptor, and therefore increased vulnerability of lymphocytes to apoptosis. For example, PAR1 deficiency has been associated with attenuated inflammatory responses in murine crescentic glomerulonephritis [20], colitis [19], and BSA-induced arthritis [21]. Treatment of mice with the thrombin inhibitor hirudin, also blocks inflammation in crescentic glomerulonephritis and in addition was recently shown to attenuate disease severity in EAE [53].

The absence of PAR1 had less effect on the ability of KLK6 to promote overall splenocyte survival, or that of B lymphocytes in the presence of dexamethasone compared to cells under resting conditions, although its absence did significantly reduce KLK6-mediated survival of CD3+ T lymphocytes. These differential effects depending on the cell death paradigm examined suggest the
involvement of additional KLK6-mediated pro-survival mechanisms when cells are under stress and that these may additionally be cell type specific. Given our prior studies that show KLK6 is also capable of activating PAR2 [9,10,11], as well as bradykinin receptor 2 [11], it is highly possible that KLK6-mediated pro-survival effects occur by activation of multiple receptors thereby triggering signaling cascades that combine to overcome or delay death signaling cascades. In this way, the ability of KLK6 to regulate survival of T and B cells would be sharply tuned by differential expression of receptors activated by KLK6 in response to changing environmental cues.

That KLK6 mediates its pro-survival effects in a receptor dependent fashion is also supported by observations herein which show as little as 5 min exposure to KLK6 was sufficient to drive survival in the short term (i.e. 24 hr). Of interest in this regard, only continual KLK6 exposure, but not short pulses up to 60 min in duration, were able to delay cell death over more prolonged culture periods.

KLK6 was shown to affect the balance of pro- and anti-apoptotic members of the Bcl-2 family. In whole splenocyte populations challenged with campothecin or ConA, KLK6 upregulated the pro-survival protein Bcl-XL and suppressed levels of the pro-apoptotic BH3 only family member Bim. Interestingly, while KLK6 suppressed Bim in whole splenocyte cultures under all conditions examined, its ability to up regulate Bcl-XL was only detected in cells undergoing an additional stress, such as campothecin or ConA, but not in resting cells. These results support the concept that KLK6 promotes survival in part by the integration of multiple signaling pathways, including those seen only in the face of cellular stress. While much remains to be learned regarding the signaling pathways triggered by KLK6 to alter immune cell survival under different conditions, the ability of KLK6 to strongly suppress Bim is of particular interest since this BH3 only family member is known to play an essential role in lymphoid and myeloid cell homeostasis [54], in the deletion of autoreactive T [55] and B cells [56], in addition to the shut down of acute T cell immune responses [33,35]. Given the elevated levels of KLK6 in MS patient serum and in active MS lesions we hypothesize one role may be to prolong inflammatory cell survival by altering levels of Bcl-2-family members. The current findings point to the need for additional studies to dissect the signaling cascades elicited by KLK6 in different immune cell subsets and its impact on their functional properties in vivo.

Collectively, these in vitro studies define KLK6 a possible new participant in the molecular signaling cascades that regulate immune cell life and death. Given the relatively widespread distribution of KLK6 in human tissues [3,58,59], and increasing awareness of its regulation in disease [1,4,28,35,60,61,62,63], this novel enzyme is in a position to play an important regulatory role in immune-related disorders, including but not limited to MS. Since insufficient lymphocyte apoptosis is a well known participant in autoimmune and lymphoproliferative disease, but in excess can promote immunodeficiency, approaches that target KLK6 may hold new promise for the treatment of diseases with an inflammatory substrate.

Author Contributions
Conceived and designed the experiments: IAS, BE, BC, AGV, AB. Performed the experiments: IAS BE BAC JW AGV ALB DNR. Analyzed the data: IAS BE BAC AGV ALB. Contributed reagents/materials/analysis tools: HY SIB MB. Wrote the paper: IAS BE BAC ALB.

References
1. Scarsibich IA, Blaber SI, Luchinetti CF, Genain CP, Blaber M, et al. (2002) Activity of a newly identified serine protease in CNS demyelination. Brain 125: 1283–1296.
2. Christophii GP, Jackson PJ, Blaber SI, Blaber M, Rodriguez M, et al. (2004) Distinct promoters regulate tissue-specific and differential expression of kallikrein 6 in CNS demyelinating disease. J Neurochem 91: 1439–1449.
3. Scarsibich IA, Blaber SI, Tingling JT, Rodriguez M, Blaber M, et al. (2006) Potential scope of action of tissue kallikreins in CNS immune-mediated disease. J Neuroimmunology 178: 167–176.
4. Scarsibich IA, Linho R, Vandell AG, Keegan M, Blaber SI, et al. (2008) Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration. Biol Chem 389: 739–745.
5. Blaber SI, Cirec B, Christophii GP, Bernett MJ, Blaber M, et al. (2004) Targeting kallikrein 6-proteolysis attenuates CNS inflammatory disease. FASEB J 19: 920–922.
6. Bernett MJ, Blaber SI, Scarsibich IA, Dhanarajan P, Thompson SM, et al. (2002) Crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system. J Biol Chem 277: 24562–24570.
7. Blaber SI, Scarsibich IA, Bernett MJ, Dhanarajan P, Seavy MA, et al. (2002) Enzymatic properties of rat myelencephalon-specific protease. Biochemistry 41: 1165–1173.
8. Angelo PF, Lima AR, Alves FM, Blaber SI, Scarsibich IA, et al. (2006) Substrate specificity of human kallikrein 6: salt and glycosaminoglycan activation effects. J Biol Chem 281: 32095–32112.
9. Okonophouoou K, Hansen KK, Safiddine M, Tea I, Blaber M, et al. (2006) Proteinase-activated receptors, targets for kallikrein signaling. J Biol Chem 281: 32095–32112.
10. Okonophouoou K, Hansen KK, Safiddine M, Vertegnelle N, Tea I, et al. (2006) Kallikrein-mediated cell signalling: targeting proteinase-activated receptors (PARs). Biol Chem 387: 817–824.
11. Vandell AG, Larson N, Laxmiakanth G, Panos M, Blaber SI, et al. (2008) Proteinase-Activated Receptor Dependent and Independent Signaling by Kallikreins 1 and 6 in CNS Neuron and Astroglial Cell Lines. J Neurochem 107: 855–870.
12. Shapcovich V, Feld M, Hollenberg MD, Lugr TA, Steinhoff M (2000) Role of proteinase-activated receptors in inflammatory responses, innate and adaptive immunity. Leukocyte Biol 83: 1309–1322.
13. Mahamad V, Vaaknin A, Ahransky O, Mor M, Burgess LE, et al. (2003) Tryptase activates peripheral blood mononuclear cells causing synthesis and release of TNF-α, IL-6 and IL-1β: possible relevance to multiple sclerosis. J Neuroimmunology 138: 115–122.
14. Colongnato R, Shlopyk JR, Jendrach M, Burysek L, Syrewitz T, et al. (2003) Differential expression and regulation of protease-activated receptors in human peripheral monocytes and monocyte-derived antigen-presenting cells. Blood 102: 2645–2652.
15. Fields RC, Schoenecker JG, Hart JP, Hoffman MR, Pizzo SV, et al. (2002) Proteinase-activated receptor-2 signaling triggers dendritic cell development. Am J Pathol 162: 1817–1822.
16. Li T, Want H, He S (2006) Induction of IL-6 release from monocytes by serine proteinases and its potential mechanisms. Scand J Immunol 64: 10–16.
17. Altieri DC, Stammes SJ (1994) Protease-dependent T cell activation: ligation of effector cell proteinase receptor-1 (EPR-1) stimulates lymphocyte proliferation. Cell 155: 371–383.
18. Wec JL, Chionh YT, Ng GZ, Harbour SN, Allison C, et al. (2009) Protease Activated Receptor-1 down-regulates the murine inflammatory and humoral response to Helicobacter pylori. Gastroenterology.
19. Vergnolle N, Cellars L, Mercarcelli A, Rizzo G, Swaminathan S, et al. (2004) A role for proteinase-activated receptor-1 in inflammatory bowel diseases. J Clin Invest 114: 1444–1456.
20. Cunningham MA, Roueau E, Chen X, Couglin SR, Holdsworth SR, et al. (2000) Protease-activated receptor 1 mediates thrombin-dependent, cell-mediated renal inflammation in crescentic glomerulonephritis. J Exp Med 191: 455–462.
21. Yang YH, Hall P, Little CB, Fosang AJ, Milenkovski G, et al. (2005) Reduction of arthritis severity in protease-activated receptor-deficient mice. Arthritis Rheum 52: 1325–1332.
22. Kouzki H, O’Grady SM, Lawrence CB, Kina H (2009) Proteases induce production of thymic stromal lymphopoietin by airway epithelial cells through protease-activated receptor-2. J Immunol 183: 1427–1434.
23. Ferrell WR, Lockhart JC, Kelso EB, Dunning L, Plevin R, et al. (2003) Essential role for proteinase-activated receptor-2 in arthritis. J Clin Invest 113: 35–41.
24. Kavagoe J, Takaiwa T, Matsuoito J, Taniya M, Merek SE, et al. (2002) Effect of proteinase-activated receptor-2 deficiency on allergic dermatitis in the mouse ear. Jpn J Pharmacol 88: 77–94.
25. Noorbakhsh F, Tsutsui S, Vergnolle N, Boven LA, Shariat N, et al. (2006) Essential role for proteinase-activated receptor-2 in experimental autoimmune encephalomyelitis and multiple sclerosis. J Exp Med 203: 425–435.
26. Laxmiakanth G, Blaber SI, Bernett MJ, Scarsibich IA, Juliano MA, et al. (2005) 1.70 A X-ray structure of human apo kallikrein 1: structural changes upon peptide inhibitor/substrate binding. Proteins 60: 802–814.
27. Song Q, Chao J, Chao L (1996) High level of circulating human tissue kallikrein induces hypotension in a transgenic mouse model. Clin Exp Hypertens 18: 975–993.
28. Diamandis EP, Yousef GM, Soossiapillai AR, Bunting P (2000) Human kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma. Clin Biochem 33: 579–593.
29. Zarghooni M, Soosiapillai A, Grass I, Scroilas A, Mirazimi N, et al. (2002) Decreased concentration of human kallikrein 6 in brain extracts of Alzheimer’s disease patients. Clinical Biochemistry 35: 225–231.
30. Borgono CA, Micorov MP, Diamandis EP (2004) Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res 2: 257–280.
31. Brenner D, Mak TW (2005) Mitochondrial cell death effectors. Curr Opin Cell Biol 21: 871–877.
32. Cohen GM (1997) Caspases: the executioners of apoptosis. Biochem J 326(Pt 1): 1–16.
33. Hildeman DA, Zhu Y, Mitchell TC, Bouillet P, Strasser A, et al. (2002) Activated T cell death in vivo mediated by proapoptotic Bcl-2 family member bim. Immunity 16: 759–767.
34. Chae HJ, Kang JS, Byun JO, Han KS, Kim DU, et al. (2000) Molecular mechanism of staurosporine-induced apoptosis in osteoblasts. Pharmacol Res 42: 373–381.
35. Zhang XD, Gillespie SK, Hersey P (2004) Staurosporine induces apoptosis of melanoma by both caspase-dependent and -independent apoptotic pathways. Mol Cancer Ther 3: 187–197.
36. Brown DG, Sun XM, Cohen GM (1993) Dexamethasone-induced apoptosis involves cleavage of DNA to large fragments prior to internucleosomal fragmentation. J Biol Chem 268: 3037–3039.
37. Zacharchuk CM, Mercep M, Chakraborti PK, Simons SS, Jr., Ashwell JD (2003) Rapid proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of apoptosis. Proc Natl Acad Sci U S A 100: 1119–1126.
38. Pellegrini M, Belz G, Sotiropoulou G, Stenman G, Mok SC, Sager R (1996) A novel tissue kallikrein, human kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma. Br J Cancer 74: 975–993.
39. Clements J, Hooper J, Dong Y, Harvey T (2001) The expanded human kallikrein gene family: expression and potential functions. Biol Chem 382: 5–14.
40. Lyons AB, Parish CR (1994) Determination of lymphocyte division by flow cytometry. J Immunol Methods 171: 131–137.
41. Bouillet P, Metcalf D, Huang DC, Tarlinton DM, Kay TW, et al. (1999) Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmune. Science 286: 1735–1738.
42. Bouillet P, Parton JJ, Godtffry DJ, Zhang LC, Coutlas L, et al. (2002) BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive B lymphocytes. Nature 415: 922–926.
43. Enders A, Bouillet P, Puthalakath H, Xu Y, Tarlinton DM, et al. (2003) Loss of the pro-apoptotic BH3-only Bcl-2 family member Bim inhibits BCR stimulation-induced apoptosis and deletion of autoreactive B cells. J Exp Med 198: 1119–1126.
44. Chalmers C, Balmanno K, Hadfield K, Ley R, Cook SJ (2003) Thrombin inhibits Bims (Bcl-2-interacting mediator of cell death) expression and prevents serum-withdrawal-induced apoptosis via protease-activated receptor 1. Biochem J 375: 99–109.
45. Wang Y, Lazo W, Stricker R, Reiser G (2006) Protease-activated receptor-1 protects rat astrocytes from apoptotic cell death via JNK-mediated release of the chemokine GRO/CINC-1. J Neurochem 98: 1046–1060.
46. Han MH, Hwang SI, Roy DB, Lundgren DH, Price JX, et al. (2003) Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 415: 1076–1081.
47. Steinwolf M, Badenokte J, Shpachovitch V, Rattenhoff A, Moormann C, et al. (2005) Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev 26: 1–43.
48. Taniyavkul K, Loberg RD, Mawocha SC, Day LL, John LS, et al. (2005) PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism. J Cell Biochem 96: 641–652.
49. Yang E, Boire A, Agarwal A, Nguyen N, O’Callaghan K, et al. (2009) Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis. Cancer Res 69: 6223–6231.
50. Scarisbrick IA, Sabharwal P, Cruz H, Larsen N, Vandell A, et al. (2006) Dynamic role of kallikrein 6 in traumatic spinal cord injury. Eur J Neuroscience 24: 1457–1469.
51. Chalmers C, Balmanno K, Hadfield K, Ley R, Cook SJ (2003) Thrombin inhibits Bims (Bcl-2-interacting mediator of cell death) expression and prevents serum-withdrawal-induced apoptosis via protease-activated receptor 1. Biochem J 375: 99–109.
52. Wang Y, Lazo W, Stricker R, Reiser G (2006) Protease-activated receptor-1 protects rat astrocytes from apoptotic cell death via JNK-mediated release of the chemokine GRO/CINC-1. J Neurochem 98: 1046–1060.